Staged Phase I/II Hepatitis C Prophylactic Vaccine

This study is currently recruiting participants.
Verified December 2013 by National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID) Identifier:
First received: September 15, 2011
Last updated: April 17, 2014
Last verified: December 2013

September 15, 2011
April 17, 2014
March 2012
January 2016   (final data collection date for primary outcome measure)
  • Incidence of chronic hepatitis C virus (HCV) infection at 6 months defined by persistent viremia over a period of 6 months after initial detection of primary infection. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Occurrence of clinical safety laboratory adverse events (AEs) assessed at baseline and 1 month following each vaccination, per treatment arm. [ Time Frame: Day 0 to 1 month ] [ Designated as safety issue: Yes ]
  • Occurrence of severe local and/or systemic solicited reactogenicity signs and symptoms in the 8 days (Day 0-7) after each vaccination, per treatment arm. [ Time Frame: Day 0 to 7 ] [ Designated as safety issue: Yes ]
  • Occurrence of vaccine-related serious adverse events (SAEs) from the time of first vaccination through the entire study period, per treatment arm. [ Time Frame: Day 0 to 29 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01436357 on Archive Site
Frequency of positive cell mediated immune response by treatment group (vaccine vs. placebo) measured by interferon gamma (IFN-gamma) production by T-cells in response to at least one out of the six HCV genotype 1b peptide pools in the vaccine. [ Time Frame: Within 14 days after the last vaccination (Day 56) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Staged Phase I/II Hepatitis C Prophylactic Vaccine
A Staged Phase I/II Study, to Assess Safety, Efficacy and Immunogenicity of a New Hepatitis C Prophylactic Vaccine Based on Sequential Use of AdCh3NSmut1 and MVA-NSmut

Phase I/II, double-blinded, randomized, placebo-controlled study of HCV-uninfected male and female active IDU aged 18 to 45 years. In Stage I 68 (+/-4) evaluable subjects will be enrolled and then an interim analysis of safety data will be performed. In Stage II an additional 276 (+/-4) subjects will be enrolled.

A two stage, Phase I/II, double-blinded, randomized, placebo-controlled study of hepatitis C virus (HCV)uninfected male and female injection drug users (IDU) aged 18 to 45. In this clinical trial AdCh3NSmut1 and MVA-NSMut HCV vaccine will be administered intramuscularly to 68 (+/-4) evaluable volunteers. A planned interim analysis of safety and immunogenicity will be conducted based on data through 1 week after receipt of the second vaccination. If no safety signal is detected and there is evidence of a measurable immune response to HCV then an additional 276 (+/-4) volunteers will be enrolled.

Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Hepatitis C
  • Other: Placebo
    Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.
  • Biological: MVA-NSmut
    Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10^8 plaque forming units (pfu) intramuscularly on day 56.
  • Biological: AdCh3NSmut1
    Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose, intramuscularly on day 0.
  • Placebo Comparator: Arm B (Stage I and II)
    Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56: 34 (+/-2) subjects Stage I, then 138 (+/-2) subjects at Stage II.
    Intervention: Other: Placebo
  • Experimental: Arm A (Stage I and II)
    Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose at day 0 followed by 1 dose of MVA-NSmut intramuscularly 56 days later at the dosage 1.8 x10^8 plaque forming units (pfu): 34 (+/-2) subjects Stage I, then 138 (+/-2) subjects at Stage II.
    • Biological: MVA-NSmut
    • Biological: AdCh3NSmut1
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2016
January 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Comprehension of informed consent.
  • 18-45 year old men or women with acknowledged active IDU in the past 90 days and have no travel plans that would interfere with ability to meet the study visit schedule.
  • In good general health as determined by a participating study physician and results within acceptable ranges for clinical laboratory evaluations as detailed in Appendix A.
  • Negative for antibodies to hepatitis C virus (anti-HCV).
  • Negative for HCV RNA.
  • Negative antibodies to HIV.
  • Negative for HBsAg.
  • Able and willing (in the Investigator's opinion) to comply with all study requirements.
  • Willing to allow the investigators access to their medical records.
  • Willingness to practice continuous effective contraception from the screening visit through 90 days after the last vaccination (males and females).
  • Among females, a negative pregnancy test within 24 hours prior to vaccination.
  • Agreement to refrain from blood donation during the course of the study or after the study.
  • Provide written informed consent prior to initiation of any study procedures.
  • Willing to provide contact information for study follow-up activities, including the address, name and contact information of three people who can be contacted to facilitate follow-up compliance.

Exclusion Criteria:

  • The subject is currently participating in a study that involves an experimental agent (vaccine, drug, biologic device, blood product, or medication) or has received an experimental agent within 30 days prior to enrollment in this study, or expects to receive another experimental agent during participation in this study.
  • Prior receipt of a recombinant simian or human adenoviral vaccine or MVA vaccine.
  • Administration of immunoglobulins and/or any blood products within the 90 days preceding the planned administration of the vaccine candidate.
  • Any confirmed or suspected immunosuppressive or immunodeficient state, including: HIV infection; asplenia; recurrent, severe infections.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (i.e., known hypersensitivity to aminoglycosideantibiotics or to egg proteins).
  • History of clinically significant contact dermatitis or other significant dermatological conditions such as psoriasis.
  • Any history of anaphylaxis in reaction to vaccination.
  • Pregnancy, lactation or willingness/intention to become pregnant during the study.
  • History of cancer (except for successfully treated basal cell carcinoma of the skin and cervical carcinoma in situ).
  • History of severe psychiatric illness, including severe depression, history of suicidal ideation, suicidal attempts, or psychosis requiring medication. The subject has a diagnosis of schizophrenia, bi-polar disease, or other severe (disabling) chronic psychiatric diagnosis that is uncontrolled and would interfere with the ability to adhere to the protocol.
  • Any other serious chronic illness requiring hospital specialist supervision.
  • Suspected or known current alcohol abuse as defined by a score of 10 or more on the Alcohol Use Disorders Identification Test (AUDIT) C test (a standardized screening tool used to identify hazardous drinkers or those with active alcohol use disorders, including abuse or dependence).
  • At high risk of HIV infection by the following criteria (adapted from HIV Network for Prevention Trials (HIVNET) behavioral criteria for high risk of HIV): (1) sexually active male who has sex with men (MSM), defined as (i) male who has had anal sex with male sexual partner or partners in the past year or (ii) a male who exchanged sex with male partner(s) for money or drugs in the past year; and (2) female and in a current relationship with a high risk male (active MSM, HIV positive male).
  • Any other significant disease, disorder or finding, which, in the opinion of the Investigator, may put the subject at risk because of participation in the study, may influence the result of the study, or may influence the subject's ability to participate in the study.
  • History of or current diagnosis of Diabetes mellitus.
  • History of or current diagnosis of autoimmune disease.
  • History of or current cardiac disease including history of myocardial infarction or arrhythmia.
  • Current diagnosis of active liver disease.
  • History of seizure disorder or currently taking anti-convulsant therapy that would interfere with safety evaluation.
  • Uncontrolled hypertension (defined as systolic blood pressure being greater than 140mm Hg or diastolic blood pressure being greater than 90mm Hg).
  • History of splenectomy.
  • Long term immunosuppressive use (defined as taken for 14 days or more in total at any time during the past 180 days) of high dose oral or parenteral glucocorticoids (high dose defined as prednisone >/=20 mg total daily dose, or equivalent dose of other glucocorticoids); or high-dose inhaled steroids (high dose defined as >800 mcg/day of beclomethasone dipropionate or equivalent); or any use of hepatotoxic or non-FDA approved medication.
  • Have an acute illness, including an oral temperature greater than or equal to 100.4 degrees Fahrenheit, within 7 days prior to the first vaccination.
  • Immunization against another pathogen within 14 days of planned injection.
18 Years to 45 Years
Contact: Kimberly Page (415) 597-4954
United States
10-0069, N01AI40074
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP